Prana Biotechnology's (PRAN) phase II study of PBT2 in Alzheimer's disease failed, the company announced Monday morning.
Shares of Prana are down 75% to $2.51 in pre-market trading.
The experimental PBT2 did not meet the study's primary endpoint of a statistically significant reduction in levels of beta amyloid plaque in the brains of patients with prodromal or mild Alzheimer's, as measured using PET imaging.
PBT2 also failed to demonstrate an improvement in brain metabolic activity, cognition or function compared to placebo.
A previous phase II study of PBT2 in Huntington's disease also failed, although Prana insists the study was positive and plans to conduct a confirmatory study in the future.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/03/16 - 17:03 PM EDT
05/03/16 - 14:00 PM EDT
05/03/16 - 11:00 AM EDT
05/03/16 - 08:17 AM EDT
05/03/16 - 07:58 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.